ADBE vs PFE: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
Adobe Inc. · Technology
$219.72
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(12.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
PFE |
| Current Price |
$219.72 |
$25.22 |
| Fair Value Estimate |
$318.59 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$87.3B |
$143.7B |
| Forward P/E |
12.6x
|
19.2x
|
| EV / EBITDA |
9.0x
|
12.3x
|
| Price / Sales |
3.5x
|
2.3x
|
| Price / FCF |
8.2x
|
15.2x
|
| Revenue Growth YoY |
+12.7%
|
+5.4%
|
| Gross Margin |
89.1%
|
69.3%
|
| Operating Margin |
36.1%
|
23.4%
|
| Return on Equity |
62.4%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
12.17%
|
6.6%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Adobe Inc. is a leading software company specializing in digital media and digital experience solutions, driven primarily by subscription-based revenue models. The company benefits from a high-quality business model characterized by a durable competitive moat, strong margins with a gross margin of 89.1% and operating margin of 36.1%, and robust return on equity at 62.4%. Despite solid revenue gro…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
ADBE |
PFE |
| Zone Low |
$238.94 |
$19.44 |
| Zone High |
$270.80 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|